China Medical System Holdings Announces Positive Phase 3 Trial Results for Ruxolitinib Cream in Chinese Atopic Dermatitis Patients

Reuters
09/26
China Medical System Holdings Announces Positive Phase 3 Trial Results for Ruxolitinib Cream in Chinese Atopic Dermatitis Patients

China Medical System Holdings Ltd. has announced positive results from a Phase 3 clinical trial evaluating ruxolitinib cream in Chinese patients with mild to moderate atopic dermatitis. The randomized, double-blind, placebo-controlled, multi-centre study enrolled 192 patients and was led by Shanghai Dermatology Hospital. The trial met its primary endpoint, with 63.0% of patients treated with ruxolitinib cream achieving an Investigator's Global Assessment $(IGA)$ of 0 or 1 with at least two grades of reduction from baseline at week 8, compared to 9.2% in the placebo group (P<0.001). The key secondary endpoint was also met, with 78.0% of patients in the ruxolitinib group achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index (EASI 75), compared to 15.4% for placebo (P<0.001). The safety profile showed that treatment-emergent adverse events were mostly mild or moderate, with no discontinuations due to adverse events. Results of the trial have already been announced by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Medical System Holdings Ltd. published the original content used to generate this news brief on September 26, 2025, and is solely responsible for the information contained therein.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10